WALPAR (WALPAR) fundamentals
WALPAR is a listed company, part of the Pharmaceuticals sector, listed on the NSE as WALPAR (ISIN INE0G2G01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What WALPAR does
Walpar Nutritions Limited is an India-based company, which is engaged in manufacturing and trading of pharmaceutical, nutraceutical, herbal and ayurvedic commodities. It also manufactures various private label/third party brands for different companies across the country and overseas, as well as for their own brand sales. It is a manufacturer of various types of nutraceutical formulation, pharmaceutical ingredients, and pharmaceutical formulations. It specializes in contract manufacturing, raw materials trading, and direct selling. Its portfolio consists of tablets, capsules, powder/sachets, and oral liquids. Its products include Pcos Care Forte, Procive-F, Procive-M, Proplus, BIOMID, FERROF, FTM-plus, FTW-plus, G-Flora INOSIA-F, Joint-CR, NI-1000, Ortin-5, Ova-Wom, PCOS-CARE, Refitil-F, Refitil-M, Seagut, Spinac, TRIVITA, flaxseed- Oil, Ironica-CR, Magorich, PDF, PIYO, and Ashyuka Plus. Its subsidiaries include Walpar Wellness Private Limited and Walpar Nutri Science Private Limited.
Valuation and market data
| Last close | ₹22.40 |
|---|---|
| Market capitalisation | ₹25 crore |
| Enterprise value | ₹24 crore |
| P/E (TTM) | 2.42 |
| Price to book | 1.31 |
| Price to sales (TTM) | 0.13 |
| Book value per share | ₹17.07 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹65 crore | ₹3 crore | ₹2 crore | 0.00 |
| Mar 2025 | ₹60 crore | ₹2 crore | ₹2 crore | 1.80 |
| Mar 2024 | ₹51 crore | ₹1 crore | ₹1 crore | 1.19 |
| Mar 2023 | ₹29 crore | ₹0 crore | ₹0 crore | 0.65 |
| Mar 2022 | ₹27 crore | ₹0 crore | ₹0 crore | 0.99 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 68.8% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 31.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.